Navigation Links
Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
Date:2/14/2008

CAMBRIDGE, England, February 14 /PRNewswire/ -- Executives from Senexis and O2H, both located in Cambridge, UK, announced an agreement under which O2H will provide synthetic and computational chemistry services to the drug discovery programmes at Senexis on an FTE basis.

"We believe our collaboration with O2H leverages the complementary expertise of both organisations and will benefit our search for new therapeutics to treat ageing-related diseases by helping Senexis increase the return on its chemistry research budget" said David Scopes, BSc, MSc, PhD - Chief Scientific Officer at Senexis.

Senexis, a recipient of recent Wellcome Trust funding, is a drug development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia, type II diabetes and dialysis related amyloidosis. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of these different diseases. Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Senexis is funded by BTG plc and the Wellcome Trust. Further information on Senexis can be found at http://www.senexis.com

O2H has its global HQ in the Science Park, Cambridge, UK, project offices in Boston and Tokyo, and a talented team of scientists in its world class discovery research centre in Ahmedabad, India. "Our scientific team in India with our project offices around the world helps our partners to maximise the value of their drug discovery programmes, from initial planning through to lead generation and lead optimisation thereby delivering enormous advantages to our growing portfolio of global clients," says Sunil Shah, CEO, O2H.

Further information on O2H can be found at http://www.oxygenhealthcare.com.

Please contact info@oxygenhealthcare.com

SENEXIS LIMITED OXYGEN HEALTHCARE LTD

Babraham Research Campus 23 Cambridge Science Park

Babraham, Cambridge, UK Cambridge, UK

CB22 3AT CB4 0EY

High resolution logos can be downloaded from http://www.oxygenhealthcare.com/senexis/logos.zip


'/>"/>
SOURCE Senexis and O2H (Oxygen Healthcare)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
2. GeoPharma Announces Record Revenues in Third Quarter Results
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
6. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
7. NightHawk Radiology Holdings, Inc. Announces Senior Executive Departures
8. VLST Corporation Announces Board and Executive Management Appointments
9. Martek to Announce First Quarter 2008 Results on March 5, 2008
10. Advance Nanotech Announces Shareholder Proxy Vote Results
11. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 19, 2017 , ... WHO: Peggy ... infections through education and advocacy. Founded in 2010 in memory of a single-parent ... the foundation has become the most-consulted source for patient-focused information on C. diff ...
(Date:4/19/2017)... IRVINE, Calif. , April 19, 2017 /PRNewswire/ ... Rx Drug Abuse and Heroin Summit ,  Proove® ... clinical study analyzing genetics, environmental, and lifestyle factors ... researchers from the University of Southern California (USC), ... , and Proove publish results showing that ...
(Date:4/19/2017)... WALTHAM, Mass. , April 19, 2017 /PRNewswire/ ... that results from the multi-center Procalcitonin MOnitoring SEpsis ... 2017 print issue of Critical Care Medicine ... Predicts Mortality in Severe Sepsis Patients: Results From ... the use of the B·R·A·H·M·S PCT (procalcitonin) assay ...
(Date:4/18/2017)... ... ... For a historic seventh consecutive year, Benchmark Research along with PMG Research Associates ... the top two Clinical Research Sites or Network. Benchmark Research has been ... previously, and first runner up the other three years. The only awards ceremony dedicated ...
Breaking Biology Technology:
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/23/2017)... 23, 2017 The report "Gesture Recognition and Touchless Sensing ... Geography - Global Forecast to 2022", published by MarketsandMarkets, the market is expected ... 29.63% between 2017 and 2022. Continue Reading ... ... ...
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
Breaking Biology News(10 mins):